Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUMATRIPTAN vs SUMATRIPTAN SUCCINATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial blood vessels and inhibits release of pro-inflammatory neuropeptides.
Acute treatment of migraine with or without aura,Acute treatment of cluster headache episodes
Acute treatment of migraine with or without aura,Acute treatment of cluster headache episodes
Sumatriptan is available as oral tablets (25 mg, 50 mg, 100 mg), subcutaneous injection (6 mg/0.5 m L), and nasal spray (5 mg, 20 mg). For acute migraine: oral: 50-100 mg at onset, may repeat after 2 hours (max 200 mg/day). Subcutaneous: 6 mg at onset, may repeat after 1 hour (max 12 mg/24h). Nasal spray: 20 mg in one nostril at onset, may repeat after 2 hours (max 40 mg/day).
50-100 mg orally at onset of migraine; may repeat after 2 hours if needed, max 200 mg/day. 6 mg subcutaneously as a single dose; may repeat after 1 hour if needed, max 12 mg/day. 20 mg intranasally as a single dose; may repeat after 2 hours if needed, max 40 mg/day.
2.5 hours (range 1–4 h); clinically relevant for redosing interval of ≥2 h.
Terminal elimination half-life: approximately 2 hours (range 1–4 hours). Clinical context: Short half-life supports use for acute migraine attacks; no accumulation with standard dosing.
Primarily via monoamine oxidase A (MAO-A); minor via cytochrome P450 (CYP) enzymes.
Hepatic via monoamine oxidase (MAO-A); some CYP450 involvement (CYP1A2, CYP3A4 minor).
60% renal (as indole acetic acid metabolite), 40% fecal; <3% unchanged in urine.
Primarily renal (60% as unchanged drug and metabolites, 40% via feces); approximately 20% unchanged in urine. Minor biliary excretion.
14–21%, primarily to albumin and alpha-1-acid glycoprotein.
14–21% (low binding; primarily to albumin and alpha1-acid glycoprotein).
2.0–3.3 L/kg; indicates extensive tissue distribution.
2.4 L/kg (range 2.0–3.0 L/kg). Indicates extensive extravascular distribution, crossing blood-brain barrier to reach central 5-HT1 receptors.
Oral: 15% (due to first-pass metabolism); subcutaneous: 97%; intranasal: 17% (with variability).
Subcutaneous: 96% (complete); Oral: 15% (low due to first-pass metabolism); Intranasal: 15–17% (relative to SC); Rectal (suppository): ~20%.
No specific dose adjustment is recommended for renal impairment. However, sumatriptan and its metabolites are excreted renally, and caution is advised in severe renal impairment (Cr Cl <15 m L/min). No specific GFR-based guidelines are established.
No specific dose adjustment required for GFR ≥15 m L/min. For GFR <15 m L/min, triptans are generally avoided; hemodialysis does not remove sumatriptan.
Contraindicated in severe hepatic impairment (Child-Pugh C). For mild to moderate hepatic impairment (Child-Pugh A or B): oral maximum dose is 50 mg; nasal spray: 5 mg single dose; subcutaneous: no specific adjustment, but caution advised due to reduced clearance.
Contraindicated in severe hepatic impairment (Child-Pugh Class C). In mild to moderate impairment, no dose adjustment recommended; use with caution.
Not approved for pediatric use <18 years. However, off-label: adolescent (12-17 years): oral 25-100 mg at onset, may repeat after 2 hours (max 200 mg/day). Subcutaneous: 3-6 mg at onset (based on weight, e.g., 0.06 mg/kg). Nasal spray: 5-20 mg at onset.
Adolescents aged 12-17: 10 mg intranasally as a single dose; may repeat once after 2 hours if needed, max 20 mg/day. Pediatric use <12 years not established.
Limited data in elderly. Start with the lowest effective dose (e.g., oral 25 mg, subcutaneous 3 mg, nasal spray 5 mg). Caution due to potential for cardiovascular risk, hypertension, and reduced hepatic/renal function. Avoid in patients with uncontrolled hypertension or ischemic heart disease.
Elderly patients have increased risk of coronary artery disease; contraindicated if CAD or other vascular disease suspected. Start at low end of dosing range; monitor for adverse effects.
Not recommended for use in patients with risk factors for coronary artery disease (e.g., hypertension, diabetes, smoking) unless a cardiovascular evaluation confirms absence of coronary artery disease.
Not recommended for use within 24 hours of another 5-HT1 agonist or ergotamine-containing medication due to risk of coronary vasospasm.
Risk of myocardial ischemia, infarction, and Prinzmetal's angina,Life-threatening serotonin syndrome with concomitant serotonergic drugs,Elevations in blood pressure,Increased risk of cerebrovascular events,Overuse headache with frequent use
Risk of myocardial ischemia, infarction, and arrhythmia; risk of cerebrovascular events; serotonin syndrome (especially with SSRIs/SNRIs); medication overuse headache; coronary artery disease risk assessment before use.
Ischemic heart disease,History of myocardial infarction,Uncontrolled hypertension,Hemiplegic or basilar migraine,Concomitant use of MAO-A inhibitors or within 2 weeks of discontinuation,Severe hepatic impairment,Hypersensitivity to sumatriptan
Ischemic heart disease, history of myocardial infarction, coronary vasospasm (Prinzmetal angina), peripheral vascular disease, cerebrovascular disease, uncontrolled hypertension, hemiplegic or basilar migraine, use within 24 hours of ergotamine derivatives or other 5-HT1 agonists, concomitant MAO-A inhibitor use or within 2 weeks of discontinuation, severe hepatic impairment.
No significant food interactions. Avoid alcohol during migraine attacks as it can worsen headaches. May be taken with or without food.
No clinically significant food interactions reported. Ingestion with food may delay absorption but does not affect efficacy. Avoid alcohol during migraine attacks as it may exacerbate headache.
FDA Pregnancy Category C. In first trimester, no increased risk of major congenital malformations from available data; however, animal studies show embryo lethality and increased malformations at high doses. Second and third trimester risks include potential for uterine hypertonus and fetal hypoxia during maternal use for migraine attacks; avoid during third trimester due to risk of premature uterine contractions.
Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal abnormalities (e.g., omphalocele, cranioschisis) at high doses. Second/third trimesters: No well-controlled studies; potential for uterine hypertonus and reduced placental perfusion; use only if benefit outweighs risk.
Sumatriptan is excreted into human breast milk with a relative infant dose of 3.5% of maternal weight-adjusted dose (M/P ratio approximately 0.6-4.3). Clinical studies show no adverse effects in breastfed infants; however, wait at least 12 hours after injection or 24 hours after oral dose to breastfeed to minimize exposure.
Excreted in breast milk; M/P ratio 2.1:1. Limited infant exposure; consider avoiding breastfeeding for 12 hours post-dose. Monitor infant for irritability, sleep disturbance.
No specific dose adjustments required for pregnancy based on pharmacokinetic changes; however, lower starting doses may be considered due to increased sensitivity to vascular effects. Avoid use in preeclampsia or uncontrolled hypertension.
No specific dose adjustment required; however, pharmacokinetic changes (increased plasma volume, altered metabolism) may reduce efficacy. Use lowest effective dose; avoid IV or high SQ doses near term due to risk of uterine hypertonus.
Sumatriptan is a 5-HT1B/1D receptor agonist used for acute migraine. It is available in oral, nasal, subcutaneous, and rectal formulations. Onset of action is fastest with subcutaneous injection (10-15 minutes). Avoid use within 24 hours of other triptans or ergot alkaloids. Contraindicated in patients with ischemic heart disease, cerebrovascular disease, uncontrolled hypertension, or hemiplegic/basilar migraine. Monitor for serotonin syndrome when combined with SSRIs/SNRIs.
Sumatriptan succinate is a serotonin 5-HT1B/1D receptor agonist used for acute migraine and cluster headache. Administer subcutaneously for fastest onset (10-15 min). Contraindicated in patients with ischemic heart disease, Prinzmetal's angina, uncontrolled hypertension, or within 24 hours of other triptans or ergotamine derivatives. Avoid within 2 weeks of MAO-A inhibitors. A second dose may be given after 1 hour if no response, but do not exceed 12 mg/24h subcutaneously (tablets: 200 mg/24h; nasal: 40 mg/24h). Injection site reactions are common but benign. Do not use for hemiplegic or basilar migraine.
Take sumatriptan at the first sign of migraine headache for best results.,Do not exceed the recommended dose: maximum 100 mg orally or 20 mg intranasally per single dose, with a maximum of 200 mg daily for oral formulations.,Seek emergency medical attention if you experience chest pain, shortness of breath, irregular heartbeat, or signs of stroke.,Avoid driving or operating machinery until you know how sumatriptan affects you, as it may cause dizziness or drowsiness.,Inform your doctor if you have heart disease, high blood pressure, or are pregnant or breastfeeding.
Take sumatriptan at the first sign of a migraine attack; do not use for prevention.,If injection, use auto-injector as directed; rotate injection sites (e.g., thigh, upper arm).,Seek emergency care if you experience chest pain, shortness of breath, irregular heartbeat, or sudden severe abdominal pain.,Do not drive or operate machinery if dizziness or drowsiness occurs after dosing.,Avoid using more than prescribed; do not combine with other triptans or ergotamine drugs within 24 hours.,Report any symptoms suggestive of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate) if taken with SSRIs or SNRIs.
"Concurrent use of sumatriptan, a serotonin 5-HT1B/1D receptor agonist, and rasagiline, a selective monoamine oxidase B (MAO-B) inhibitor, can lead to serotonin syndrome due to excessive serotonergic activity in the central nervous system. Rasagiline inhibits the metabolism of serotonin, while sumatriptan indirectly increases serotonin release; their combination may result in life-threatening neuromuscular excitation, autonomic instability, and altered mental status. Symptoms may include hyperthermia, rigidity, myoclonus, and rapid fluctuations in vital signs, requiring immediate medical intervention."
"Sumatriptan, a 5-HT1B/1D receptor agonist used for migraine, and sulpiride, a dopamine D2 receptor antagonist with atypical antipsychotic properties, may exhibit additive or synergistic effects on the central nervous system. This combination can potentially increase the risk of serotonin syndrome (due to sumatriptan's serotonergic activity) and may also lead to enhanced extrapyramidal symptoms or neuroleptic malignant syndrome via combined dopaminergic antagonism. Clinical outcomes may include hyperthermia, rigidity, altered mental status, and autonomic instability."
"The combination of sumatriptan (a 5-HT1B/1D receptor agonist) and paroxetine (a selective serotonin reuptake inhibitor) increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. This interaction is due to additive serotonergic effects, as both drugs enhance serotonin activity in the central nervous system. Clinical outcomes range from mild symptoms (tremor, hyperreflexia, diaphoresis) to severe manifestations (hyperthermia, rigidity, seizures) and require immediate medical attention."
"Concurrent use of sumatriptan, a serotonin 5-HT1B/1D receptor agonist, and rasagiline, a selective monoamine oxidase B (MAO-B) inhibitor, can lead to serotonin syndrome due to excessive serotonergic activity in the central nervous system. Rasagiline inhibits the metabolism of serotonin, while sumatriptan indirectly increases serotonin release; their combination may result in life-threatening neuromuscular excitation, autonomic instability, and altered mental status. Symptoms may include hyperthermia, rigidity, myoclonus, and rapid fluctuations in vital signs, requiring immediate medical intervention."
"Sumatriptan, a 5-HT1B/1D receptor agonist used for migraine, and sulpiride, a dopamine D2 receptor antagonist with atypical antipsychotic properties, may exhibit additive or synergistic effects on the central nervous system. This combination can potentially increase the risk of serotonin syndrome (due to sumatriptan's serotonergic activity) and may also lead to enhanced extrapyramidal symptoms or neuroleptic malignant syndrome via combined dopaminergic antagonism. Clinical outcomes may include hyperthermia, rigidity, altered mental status, and autonomic instability."
"The combination of sumatriptan (a 5-HT1B/1D receptor agonist) and paroxetine (a selective serotonin reuptake inhibitor) increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. This interaction is due to additive serotonergic effects, as both drugs enhance serotonin activity in the central nervous system. Clinical outcomes range from mild symptoms (tremor, hyperreflexia, diaphoresis) to severe manifestations (hyperthermia, rigidity, seizures) and require immediate medical attention."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUMATRIPTAN vs SUMATRIPTAN SUCCINATE, answered by our medical review team.
SUMATRIPTAN is a 5-HT1 Agonist that works by Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.. SUMATRIPTAN SUCCINATE is a 5-HT1 Agonist that works by Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial blood vessels and inhibits release of pro-inflammatory neuropeptides.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUMATRIPTAN and SUMATRIPTAN SUCCINATE depend on the specific clinical indication. These are both 5-HT1 Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUMATRIPTAN is: Sumatriptan is available as oral tablets (25 mg, 50 mg, 100 mg), subcutaneous injection (6 mg/0.5 m L), and nasal spray (5 mg, 20 mg). For acute migraine: oral: 50-100 mg at onset, may repeat after 2 hours (max 200 mg/day). Subcutaneous: 6 mg at onset, may repeat after 1 hour (max 12 mg/24h). Nasal spray: 20 mg in one nostril at onset, may repeat after 2 hours (max 40 mg/day).. The standard adult dose of SUMATRIPTAN SUCCINATE is: 50-100 mg orally at onset of migraine; may repeat after 2 hours if needed, max 200 mg/day. 6 mg subcutaneously as a single dose; may repeat after 1 hour if needed, max 12 mg/day. 20 mg intranasally as a single dose; may repeat after 2 hours if needed, max 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUMATRIPTAN and SUMATRIPTAN SUCCINATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUMATRIPTAN is classified as Category D/X. FDA Pregnancy Category C. In first trimester, no increased risk of major congenital malformations from available data; however, animal studies show embryo lethality and increased m. SUMATRIPTAN SUCCINATE is classified as Category D/X. Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal abnormalities (e.g., omphalocele, cranioschisis) at high doses. Second/third trimeste. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.